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Abstract 
Background: Chronic renal disease (CKD) is a determinant of coronary artery calcification 
(CAC), which is a predictor of cardiovascular events. However, in a population without CKD, the 
association between CAC and renal function is unclear. CAC is affected by sex. This study aimed 
to determine whether serum cystatin C, a sensitive marker of kidney function, or sex differences 
are associated with CAC in patients without CKD.  
Methods: We evaluated 456 consecutive patients (61±13 years, 42% women) without CKD and 
evidence of coronary artery disease. The CAC (Agatston) score was examined by multidetector 
computed tomography. 
Results: When patients were categorized into three CAC groups based on the Agatston score, 
mild (<10), moderate (11–399), and severe (≥400) in each sex, serum cystatin C levels was 
gradually increased by severity of CAC in women, but not men. Receiver operating characteristic 
curve analysis showed that, in women, a cutoff value of 0.97 mg/l for cystatin C discriminated 
patients with severe CAC with a sensitivity of 71% and specificity of 77% (area under the curve, 
0.74; 95% CI: 0.62–0.86; P<0.01). Multivariate logistic analysis showed that serum cystatin C 
was not associated with severe CAC in all patients and men, but this association was observed in 
women (OR: 7.80 for cystatin C > 0.97mg/l, 95% CI: 1.76–34.6, p<0.01). 
Conclusion: Higher serum cystatin C levels are associated with greater CAC in women without 
CKD. Measurement of cystatin C may be useful for identifying women who are at high risk for 
cardiovascular disease. 
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Introduction 
Chronic kidney disease (CKD) is a worldwide health problem that carries a substantial risk for 
cardiovascular morbidity and death [1, 2]. Serum creatinine concentrations or creatinine-based 
estimating equations have served as the primary tool for evaluating kidney function in clinical 
practice [3]. However, the creatinine-based Modification of Diet and Renal Disease study formula 
for estimating glomerular filtration rate (GFR) still has substantial inaccuracy when applied to 
healthy persons and older individuals [4]. Recent studies have shown that cystatin C is a more 
reliable index of renal function [5]. Cystatin C is a small serine protease inhibitor that plays 
pleiotropic roles in human vascular pathophysiology [6]. Cystatin C is also a strong predictor of 
future coronary artery disease (CAD), ischemic stroke, and heart failure. [7-11] 
Coronary artery calcification (CAC) is an established marker of subclinical atherosclerosis and 
an independent predictor of future coronary heart disease [12-14]. Previous studies have 
demonstrated a relation between CKD and greater CAC [15-19]. However, the effect of serum 
cystatin C levels on CAC in a population without CKD has not fully determined. Furthermore, 
several studies have shown that the severity of CAC is affected by sex [20-22]. 
Accordingly, this study aimed to evaluate the association between cystatin C levels and CAC in 
patients without evidence of CKD and CAD. We also aimed to evaluate the effect of sex on the 
association between cystatin C levels and CAC. 
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Material and Methods 
Study population 
Patients without evidence of CKD and CAD who underwent multidetector row computed 
tomography (CT) for CAC and a blood test within 7 days were retrospectively included. First, 
patients who underwent multidetector row CT to examine CAC for suspected CAD at Okayama 
University Hospital between August 2011 and July 2013 were screened (n=1273). Patients were 
excluded if they had CKD defined as estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 
m2 (n=398) and a history of coronary artery disease or coronary stents (n=63), Patients with no 
cystatin C measurements within 7 days (n=342) and no evaluation of coronary ischemia (n=14) 
were also excluded. Finally, a total of 456 patients were included in the analysis. 
This study was approved by the Ethics Committee of Okayama University Graduate School of 
Medicine, Dentistry, and Pharmaceutical Sciences (Okayama, Japan). All of the patients provided 
written, informed consent. The study was conducted in accordance with the latest version of the 
Declaration of Helsinki. 
Laboratory tests 
Serum cystatin C levels were measured by an immunological turbid metric assay (Nescoat GC 
Cystatin C; Alfresa Pharma, Osaka, Japan) as previously described [11]. Other laboratory 
parameters were measured using standard laboratory techniques with an automatic analyzer. eGFR 
was calculated by the following equation: eGFR (ml/min/1.73 m2) = 194×Cr−1.094×age−0.287× (0.739 
if female) [23] CKD was defined as eGFR <60 ml/min/1.73 m2. 
CT protocol 
For CAC imaging, a 64-slice non-enhanced CT scan was obtained with a diagnostic CT 
scanner (Somatom Definition Flash; Siemens Medical Solutions, Germany), as previously 
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described [24]. The parameters were as follows: detector collimation was 64×0.6 mm equaling 
a slice acquisition of 128×0.6 mm using the flying focal spot technique; table pitch was 
adapted to heart rate (0.17–0.38); rotation time was 275 ms; the tube current–time product was 
360 mA; and tube voltage was 120 kVp. CAC was quantified using the standard Agatston 
calcium scoring algorithm [25]. The cohort was stratified into four groups according to the 
CAC score: CAC score of 0–9 (n=204), CAC score of 10–99 (n=111), CAC score of 100–399 
(n=125), and CAC score ≥400 (n=158). For coronary CT angiography, the initial bolus of 
contrast agent (Omnipaque 350; Daiichi Sankyo, Tokyo, Japan) was calculated as body 
weight×0.07 ml and was injected over 10 s. This was followed by a second bolus consisting of 
80% of the initial volume of contrast medium diluted to 50% with normal saline and then a 
compensatory 20% bolus of normal saline. The patients arrived at the hospital 60 min before 
the CT scan and received oral metoprolol and/or intravenous landiolol hydrochloride (0.125 
mg/kg) until the heart rate was less than 60 beats/min [26]. Coronary artery stenosis was 
evaluated on axial and curved multiplanar reformatted images using commercially available 
cardiac reconstruction software (Virtual Place, Raijin; AZE Inc., Tokyo, Japan). Evaluations 
were performed on a per-segment basis, using 16 segments as established in the American 
Heart Association segment model [27]. One experienced and trained senior cardiologist and 
two senior CT technologists performed the analyses. 
Statistical analysis 
Continuous variables with normal distribution are shown as mean ± SD and continuous 
variables with skewed distribution are presented as median (interquartile range). ANOVA or the 
Kruskal–Wallis test was applied to compare continuous variables among study groups. The chi-
square test was applied to compare categorical variables among the groups. The optimal value of 
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cystatin C that best separated the patients with severe CAC >400 was determined by constructing 
a receiver operating characteristic curve. Multivariate logistic regression analysis included all 
variables used in the univariate analysis. A p value <0.05 was considered statistically significant. 
Statistical analysis was performed using SPSS 24.0 for Windows (SPSS Inc., Chicago, IL, USA). 
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Results 
Patients’ characteristics according to sex are shown in Table 1. A total of 456 
consecutive participants (61±13 years, 58% men) were included. Men had a higher proportion of 
current smokers. With regard to biochemical parameters, women had higher levels of total 
cholesterol, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol. Serum 
levels of creatinine and cystatin C in men were significantly higher than those in women. Table 2 
shows the patients’ characteristics according to CAC scores of mild (0–9), moderate (10–399), and 
severe (>400). Age, the proportion of men, the prevalence of diabetes mellitus, and serum cystatin 
C levels were significantly higher in the highest CAC group. Furthermore, the association between 
CAC and serum cystatin C levels was analyzed according to sex. In women, serum cystatin C levels 
in the mild, moderate, and severe CAC groups gradually increased as the severity of CAC increased 
(0.87 [0.16], 0.89 [0.21], and 1.00 [0.15] mg/l, expressed as median [interquartile range], 
respectively, p<0.01), but they did not increase in men (0.95 [0.28], 0.96 [0.22], and 0.97 [0.17] 
mg/l, respectively, p=N.S.) 
Patients were then classified into tertiles (T1–T3) based on cystatin C levels. In all patients, 
T1 was 0.56–0.85 mg/l (n=150), T2 was 0.86–0.99 mg/l (n=158), and T3 was 1.00–1.70 mg/l 
(n=148). In men, T1 was 0.58–0.89 mg/l (n=97), T2 was 0.90–1.03 mg/l (n=83), and T3 was 
1.04–1.70 mg/l (n=85). In women, T1 was 0.56–0.82 mg/l (n=61), T2 was 0.83–0.93 mg/l 
(n=67), and T3 was 0.94–1.30 mg/l (n=63). A gradual increase in the Agatston score was 
observed in women, but not in all patients and men (Figure 1). 
Receiver operating characteristic curve analyses were performed. In all patients, a cutoff 
value of 0.88 mg/l for cystatin C could discriminate patients with severe CAC with a sensitivity 
of 76% and specificity of 44% (area under the curve, 0.60; 95% CI: 0.53–0.66, P=0.02). In men, 
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a cutoff value of 0.78 mg/l for cystatin C had a sensitivity of 96% and specificity of 17% (area 
under the curve, 0.51; 95% CI: 0.43–0.59, P=0.58). In women, a cutoff value of 0.97 mg/l for 
cystatin C showed a sensitivity of 71% and specificity of 77% (area under the curve, 0.74; 95% 
CI: 0.62–0.86, P<0.01). 
To confirm the association between cystatin C levels and CAC, logistic analyses were 
performed (Table 3). In all patients and men, cystatin C was not a factor involved in severe CAC. 
In women, cystatin C > 0.97mg/l was an independent factor associated with severe CAC, and this 
association remain significant after adjusting for confounding factors (odds ratio: 7.80, 95% 
confidence interval [CI]: 1.76–34.6, p<0.01). 
Furthermore, to eliminate the effect of diabetes mellitus on the association between cystatin C 
and CAC, receiver operating characteristic curve analysis and logistic analyses in patients 
without diabetes mellitus were performed. In all patients, a cutoff value of 0.95 mg/l for cystatin 
C discriminated patients with severe CAC with a sensitivity of 68% and specificity of 42% (area 
under the curve, 0.59; 95% CI: 0.50–0.69, P=0.09). In men, a cutoff value of 0.95 mg/l for 
cystatin C had a sensitivity of 67% and specificity of 54% (area under the curve, 0.50; 95% CI: 
0.38–0.63, P=0.94). In women, a cutoff value of 0.98 mg/l for cystatin C showed a sensitivity of 
71% and specificity of 22% (area under the curve, 0.74; 95% CI: 0.59–0.89, P=0.03). 
Multivariate logistic analyses showed that, in all patients, age >65 years (odds ratio: 65.1, 95% 
CI: 3.55–77.1, p<0.01) and male sex (odds ratio: 3.18, 95% CI: 1.08–9.37, p=0.03), but not 
cystatin C levels >0.95 mg/l (odds ratio: 1.49, 95% CI: 0.55–3.98, p=0.43), were factors involved 
in severe CAC. In men, age (odds ratio: 15.77, 95% CI: 3.12–79.66, p<0.01), but not cystatin C 
levels >0.95 mg/l (odds ratio: 0.79, 95% CI: 0.25–2.61, p=0.71), was involved in severe CAC. In 
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women, only cystatin C levels >0.97 mg/l were an independent factor associated with severe 
CAC (odds ratio: 12.31, 95% CI: 1.12–134.50, p=0.04). 
 
Discussion 
This study demonstrated that higher serum cystatin C levels were independently associated 
with greater CAC in women, but not in men, without CKD. Measurement of serum cystatin C 
levels could be useful for identifying individuals at risk of cardiovascular disease in women without 
CKD. 
This study clearly showed an effect of sex on the association between serum cystatin C levels 
and CAC. One potential explanation for this finding is that traditional risk factors in men affect 
CAC more than those in women. In this study population, diabetes mellitus was an independent 
factor associated with CAC >400 in men, but not in women. Therefore, the effect of diabetes 
mellitus on CAC in men may be stronger than that in women, which leads to a differential effect 
of cystatin C on CAC. Another explanation is that cystatin C may be involved in development of 
atherosclerosis in the early stage. An increase in CAC in women by the female hormone estrogen 
is slower than that in men, indicating that cystatin C is directly involved in development of 
atherosclerosis. Imai et al. reported that higher serum cystatin C concentrations were correlated 
with early-stage coronary atherosclerotic plaques among patients determined by CT coronary 
angiography without established chronic kidney dysfunction [28]. In fact, the Agatston score in 
men was much greater than that in women in study. Furthermore, our results of subanalysis without 
diabetes mellitus showed that age had a significant effect on severe CAC in men, but not in women, 
in subjects without CKD. 
Smoking is a risk factor of progression of CAC [29]. In our study, the prevalence of being a 
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current smoker in men was greater than that in women. However, our findings showed that 
smoking was not a significant factor associated with CAC in men and women. A previous study 
reported that CAC in former smokers was more severe than that in current smokers [30]. In our 
study, data regarding current or former smokers were not available. Furthermore, cystatin C levels 
were not different between non-smoking men (n=153) and smoking men (n=112) (0.96 [0.24] 
mg/l and 0.96 [0.22] mg/l, p=0.93). This finding suggested that smoking did not affect cystatin C 
levels. Further analysis including a parameter reflecting burden of smoking exposure, such as 
pack-years of smoking, is needed to clarify the effect of smoking on CAC in subjects without 
CKD. 
  Previous studies have demonstrated that serum cystatin C levels are a useful marker for 
predicting worsening or new onset of cardiovascular disease in a variety of populations [7-10]. 
There is some biological plausibility for the role of cystatin C in the pathogenesis of vascular 
disease [6]. However, whether cystatin C plays a causal role in the etiology of cardiovascular 
disease in the clinical setting remains unclear. Recently, van der Laan et al. [31] reported that 
Mendelian randomization analyses did not support a causal role of cystatin C in the etiology of 
cardiovascular disease in Caucasians. This finding suggests that cystatin C is a marker, but not a 
target, for intervention. However, predicting patients at high risk of events is critically important 
for clinical practice. Cystatin C remains important for risk assessment. 
There are several limitations in this study. First, serum cystatin C levels appear to be elevated 
in patients with hypothyroidism and depressed in those with hyperthyroidism[32]. However, this 
study did not examine thyroid hormones in all patients. Therefore, an effect of thyroid function on 
cystatin C levels cannot be denied in this study. Second, this study included patients with suspected 
CAD. Therefore, our results cannot be applied to the general population. Third, CKD was only 
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defined by eGFR in this study because data on proteinuria or microalbuminuria were not available. 
Albuminuria is a marker of kidney damage. Therefore, our results need to be interpreted with 
caution in patients with an eGFR >60 ml/min/1.73 m2 and albuminuria.  
In conclusion, serum cystatin C is an independent factor associated with CAC as a marker of 
subclinical atherosclerosis in women, but not in men, without CKD and CAD. Serum cystatin C 
could be useful for identifying female patients at high risk of cardiovascular disease without CKD. 
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Figure legend 
 
Figure 1. Box plot showing Agatston scores according to tertiles of cystatin C. 
All patients: T1, 0.56–0.85 mg/l (n=150); T2, 0.86–0.99 mg/l (n=158); and T3, 1.00–1.70 mg/l 
(n=148). Men: T1, 0.58–0.89 mg/l (n=97); T2, 0.90–1.03 mg/l (n=83); and T3, 1.04–1.70 mg/l 
(n=85). Women: T1, 0.56–0.82 mg/l (n=61); T2, 0.83–0.93 mg/l (n=67); and T3, 0.94–1.30 mg/l 
(n=63). 
*p<0.05 vs. T1 group; †p<0.05 vs. T2 group. 
 
